Skip to Main Content

Latest News

  • Ten Years of Leadership in Immunotherapy

    The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest breakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.

    Read more
  • Profs feel satisfied, snubbed by Nobel Prizes

    The Nobel Prize was awarded Monday for cancer immunology. The 2018 Nobel laureates James Allison and Tasuku Honjo found proteins known as immune checkpoints that can stop T-cells, causing them to pass over a cancer cell instead of attacking it. Checkpoint inhibitors drastically transformed the field of cancer immunology said Mario Sznol, co-director of the Cancer Immunology Program at YCC. He praised the decision to award Allison and Honjo, but said many others also deserved recognition. “One who didn’t get the Nobel Prize but made a major, major contribution to understanding this pathway and its role in the treatment of cancer is Dr. Lieping Chen, who’s here at Yale, and as far as I’m concerned, Dr. Chen also deserves part of the Nobel Prize.”

    Read more
  • Lieping Chen, MD, PhD Selected as one of this Year's Giants in Cancer Care by OncLive

    Lieping Chen, MD, PhD, co-director of the Cancer Immunology Program at Yale Cancer Center, has been selected as one of this year's Giants in Cancer Care by OncLive. Dr. Chen joins 21 respected healthcare professionals who are advancing the field of oncology by their contributions in research and clinical practice. The winners will be celebrated on May 31st at a ceremony in Chicago. Nominated by the oncology community, all finalists are selected by an elite seven-member advisory board of world-renowned oncologists. The finalists in each category are then voted on by a 100-plus member selection committee comprising the nation's leading physicians in the oncology space.

    Source: OncLive
    Read more